Navigation Links
Assurance Biosense, Inc. Receives FDA 510(k) Clearance
Date:4/17/2013

Glastonbury, CT (PRWEB) April 17, 2013

Assurance Biosense Receives FDA 510(k) Clearance to Market Alar Sensor
-Unique Nasal Ala Pulse Oximetry Sensor-
-Alar Sensing Promises High-Levels of Accuracy, Stability and Monitoring Reliability-
-Sensor Compatible with Large, Existing Installed Base of Pulse Oximeters-

Assurance Biosense, Inc., a subsidiary of Xhale, Inc., today announced receipt from the U.S. Food and Drug Administration (FDA) of 510(k) clearance to market its Assurance® Alar Sensor for monitoring of oxygen saturation of arterial hemoglobin (SpO2) and pulse rate from the nasal ala of adult and pediatric patients.

The nasal ala, the fleshy part of the nose adjacent to the opening of the nares (nostril), is a region rich in vasculature and offers a unique monitoring site for pulse oximetry. This site is fed by both the external and internal carotid arteries; the latter also provides blood to the brain. This multi-directional arterial supply provides strong, reliable photoplethysmography signals that are rapidly responsive to changes in the patient’s arterial oxygen saturation. This measurement site is less susceptible to patient movement or loss of signal due to variations in peripheral perfusion as are the extremities, and is easily accessed by an anesthesiologist during surgery.

The Assurance Alar Sensor is intended for the continuous non-invasive monitoring of SpO2 from the nasal ala of adult and pediatric patients (weighing >30kg). The single patient use sensor attaches comfortably to the nasal ala without the need for adhesives at the placement site and can easily be checked and moved by the clinician as necessary, allowing it to remain on the patient for the full length of stay. The sensor is compatible with the large installed base of monitors compatible with the Nellcor Oxisensor-II sensor.

Andrew E. Kersey, President of Assurance Biosense, stated, “We are excited to receive clearance to market our unique Assurance Alar Sensor. We plan to begin initial shipments to select customers over the coming weeks. This revolutionary new sensor offers the benefits of reliable central monitoring while using existing legacy pulse oximeters and at no additional cost to that of traditional disposable finger-tip based oximeter sensors.”

“Clinical testing has shown central monitoring of pulse oximetry to be an improvement over peripheral sites such as the finger-tips used by traditional sensors”, Mr. Kersey continued, “further improving the measurement of this vital sign and improving patient care. Compared to monitoring at the finger-tip, central pulse oximetry has been shown to offer reliable measurements during extremely low perfusion, as well as faster detection of desaturation and resaturation events particularly during low perfusion. The nose is an excellent site for ease of access during surgery, while the hands are not readily available to anesthesiologists. This first product in our portfolio will be an important foundation upon which we will add future products that capitalize on the benefits of measurement at the alar site.”

About Assurance Biosense:
Assurance Biosense, a wholly owned subsidiary of Xhale, Inc., is committed to providing clinicians with easy to use, cost effective diagnostic solutions that improve patient safety and reduce false alarms. Its Assurance PPG/oximetry sensors monitor central blood flow to the brain through placement on the nasal ala, a region rich in vasculature, fed by the external and internal carotid arteries. The unique physiology of the site provides a much stronger signal than that from a fingertip or extremity, delivering more robust pulse oximetry signals, while simultaneously enabling the monitoring of a range of critical physiologic parameters which cannot be monitored via conventional pulse oximetry.

About Xhale:
Xhale, Inc. is a medical technology innovator, developing products that transform healthcare and save lives. The company is a world leader in the use of sensors that analyze vapor and exhaled breath and is focused on novel patient-centric monitoring solutions. Its current product lines include SMART®, the world’s only definitive medication adherence monitoring system, and Assurance®, a replacement for conventional finger-based pulse oximetry which will monitor multiple patient parameters from a single-point-of-contact sensor more comfortably and conveniently, and with fewer false alarms, than finger-based pulse oximetry.

For more information, please visit http://www.assurancebio.com or contact Investor Relations at the company at ir(at)xhale(dot)com or 352.371.8488.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10640692.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Chemical Publishing Company; Author Colin Frayne of Aquassurance Inc. To Conduct Service Technician Training Course
2. UCSB professor receives award for graphene electronics research
3. Watsons Generic Yaz(R) Receives FDA Approval
4. Quanterix Receives Funding From the Department of Homeland Security to Develop Test for Botulinum Toxin
5. Life Technologies Ion Personal Genome Machine Receives San Diegos CONNECT Most Innovative New Product Award
6. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
7. Intimate Bridge 2 Conception, Inc. Receives $4.3M
8. Pacific Meso Center Receives Generous Donation to First Free-Standing Mesothelioma Research Laboratory in Los Angeles
9. BioNeutral Group Receives $400,000 in Equity Financing
10. Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
11. Arcion Receives Notice of Allowance for US Patent for Novel Topical Lidocaine Formulation for Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/20/2017)... ... 2017 , ... SSCI and Whitehouse Laboratories, divisions of Albany Molecular Research, Inc, ... by the Parenteral Drug Association (PDA), the New York Interphex Show will open on ... and more than 625 exhibitors, the educational and networking opportunities are extremely valuable. INTERPHEX ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... biotech companies, recently announced it will debut a brand new pressure vessel, the ... intelliVessel is controlled by a touch screen panel and features other revolutionary operations ...
(Date:3/20/2017)... Yorba Linda, CA (PRWEB) , ... March 20, ... ... interference and require expensive and laborious sample preparation methods in order to reduce ... is often underappreciated outside of the area of elemental analysis. , This ...
(Date:3/20/2017)... , ... March 20, 2017 , ... The fourth annual ... while innovating to make an extraordinary impact on peoples’ lives, launches today. Sponsored by ... challenge every 5 weeks and awards thousands in cash prizes to engineers, inventors and ...
Breaking Biology Technology:
(Date:3/1/2017)... BEDFORD, Mass. , March 1, 2017  Aware, ... and services, announced that Richard P. Moberg ... Officer and co-President and Chief Financial Officer and Treasurer ... will continue to serve as a member of the ... T. Russell , Aware,s co-Chief Executive Officer and co-President, ...
(Date:2/27/2017)... 2017   Strategic Cyber Ventures , the industry,s ... a $3.5 million investment in  Polarity , the first ... is DC based and is led by cybersecurity veterans ... Ron Gula , also a longtime cybersecurity veteran ... this series A round of funding. This new funding ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 ... Family of Companies (Avamere Health Services, Infinity Rehab, Signature ... research study that will apply the power of IBM ... living and health centers. By analyzing data streaming from ... insights into physical and environmental conditions, and obtain deeper ...
Breaking Biology News(10 mins):